Stockpolly
Search
Delisting riskEarnings are out
BLRX · NASDAQ · Biotechnology

BioLineRx (ADR) (BLRX)

Builds oncology assets around APHEXDA royalties and GLIX1 clinical development.

$2.66
Pre-market−0.00 (−0.08%)
At close$2.66(−3.62%)
Watchlist

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Nov 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Revenue0575512000000
Cost of revenue001116000000
Gross profit055446000000
122310101010333334
Research & development332232222233
10108876101111
Selling & marketing8−3666−8000000
General & administrative11312114101010
Other expenses0110002000000
Operating income−12−19−5−6−5−4−2−2−2−3−3−4
−4546018−2110−1
Interest income011100000000
Interest expense1−11224000000
Other non-operating income3−4−5−8−1−6−81−2−1−10
Income before tax−16−14−10−6−35−4−1−2−3−4
Net income from continuing operations−16−14−10−6−35−4−1−2−3−4
Other adjustments000000000000
Net income−16−14−10−6−35−4−1−1−3−3
EPS, basic−$0.26−$7.74−$0.36$0.24−$2.94−$1.62$2.58−$1.00−$0.22−$0.32−$0.58−$0.70
EPS, diluted−$0.26−$7.74−$0.36$0.24−$2.94−$1.62$2.58−$1.00−$0.22−$0.32−$0.58−$0.70
Weighted average shares, basic6222222244444
Weighted average shares, diluted6222222244444
EBITDA−15−1413−336−3−1−2−2−4
Depreciation & amortization011012000000
EBIT−15−1503−416−4−1−2−2−4